Tech was leading the way lower for stocks Wednesday. BTIG Chief Market Technician Jonathan Krinsky noted that while tech ...

BTIG lowered the firm’s price target on Outlook Therapeutics (OTLK) to $9 from $50 and keeps a Buy rating on the shares. The ...

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period. BTIG analyst Gray ...

Embecta (EMBC) stock gains as BTIG upgrades the stock citing an end to its patch pump program announced with its Q4 FY24 ...

BTIG Research has recently resumed Blackstone Mortgage Trust Inc (BXMT) stock to Buy rating, as announced on July 19, 2024, according to Finviz. Earlier, on June 25, 2024, Wolfe Research had initiated ...

Investors should start looking at restaurant names that have timely setups, said Jonathan Krinsky, chief market technician at ...

Zscaler (NASDAQ:ZS – Get Free Report) had its price objective upped by research analysts at BTIG Research from $205.00 to ...

Agree Realty (NYSE:ADC – Free Report) had its price objective hoisted by BTIG Research from $74.00 to $78.00 in a report ...

Fintel reports that on November 25, 2024, BTIG initiated coverage of V2X (NYSE:VVX) with a Buy recommendation. Analyst Price ...

The new Trump administration is coming in hot, with mass deportations of undocumented immigrants and threats of triggering a ...

BTIG upgraded Embecta (EMBC) to Buy from Neutral with a $26 price target Shares gained about 30% in Tuesday trading as investors rewarded ...

Fintel reports that on November 26, 2024, BTIG downgraded their outlook for Poseida Therapeutics (NasdaqGS:PSTX) from Buy to ...